Virtu Financial LLC Sells 24,479 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Virtu Financial LLC lessened its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 32.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,647 shares of the company’s stock after selling 24,479 shares during the period. Virtu Financial LLC’s holdings in Atossa Therapeutics were worth $77,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ATOS. XTX Topco Ltd bought a new position in Atossa Therapeutics in the 2nd quarter valued at $29,000. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. SG Americas Securities LLC grew its position in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after buying an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Atossa Therapeutics during the third quarter worth about $75,000. Finally, Rhumbline Advisers bought a new stake in Atossa Therapeutics in the second quarter worth about $161,000. 12.74% of the stock is owned by institutional investors.

Atossa Therapeutics Stock Down 1.0 %

NASDAQ ATOS opened at $0.98 on Friday. The firm has a market cap of $123.28 million, a P/E ratio of -4.45 and a beta of 1.21. The company’s 50 day moving average is $1.32 and its 200-day moving average is $1.32. Atossa Therapeutics, Inc. has a 12-month low of $0.71 and a 12-month high of $2.31.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ATOS shares. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research report on Thursday, December 12th. Finally, Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.